Share Name Share Symbol Market Type Share ISIN Share Description
Feedback Plc LSE:FDBK London Ordinary Share GB0003340550 ORD 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 1.725p 1.70p 1.75p 1.745p 1.725p 1.725p 722,875 11:32:31
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Electronic & Electrical Equipment 0.5 -0.3 -0.1 - 4.25

Feedback (FDBK) Latest News

Feedback News

Date Time Source Headline
14/2/201810:36ALNCFeedback Appoints David Crabb As New Chief Executive Officer
14/2/201807:28ALNCFAlliance News Flash Headline
14/2/201807:00UKREGFeedback PLC Directorate Change
09/2/201812:04UKREGFeedback PLC Holding(s) in Company
05/2/201813:56UKREGFeedback PLC Holding(s) in Company
28/12/201717:42UKREGFeedback PLC Holding(s) in Company
28/12/201717:19UKREGFeedback PLC Total Voting Rights
20/12/201709:33UKREGFeedback PLC Holding(s) in Company
30/11/201716:38UKREGFeedback PLC Result of AGM
22/11/201709:37UKREGFeedback PLC Holding(s) in Company
More Feedback News
Feedback Takeover Rumours

Feedback (FDBK) Share Charts

1 Year Feedback Chart

1 Year Feedback Chart

1 Month Feedback Chart

1 Month Feedback Chart

Intraday Feedback Chart

Intraday Feedback Chart

Feedback (FDBK) Discussions and Chat

Feedback (FDBK) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Feedback trades in real-time

Feedback (FDBK) Top Chat Posts

DateSubject
18/2/2018
08:20
Feedback Daily Update: Feedback Plc is listed in the Electronic & Electrical Equipment sector of the London Stock Exchange with ticker FDBK. The last closing price for Feedback was 1.73p.
Feedback Plc has a 4 week average price of 1.47p and a 12 week average price of 1.47p.
The 1 year high share price is 5.13p while the 1 year low share price is currently 1.38p.
There are currently 246,416,584 shares in issue and the average daily traded volume is 1,610,993 shares. The market capitalisation of Feedback Plc is £4,250,686.07.
20/12/2017
12:58
lr2: What's likely happening here is a petulant old man with a very large holding is pished off with the board of directors now he is no longer a part of it. To hurt the company he used to be an integral part of, he has decided to sell vast numbers of his shares into the market rather than arrange an orderly market disposal, The result - a forcing down of the share price from 3.75p when he started selling to today's opening 1.6p. Even though he is losing vast amounts of money on his remaining holding he views that as worthwhile to his cause. If anyone has an alternative viewpoint on the man's sales then I'd be happy to hear it espoused here.
20/12/2017
11:58
lr2: If TB continues at his current rate of selling 7 million shares a month, he will be done by mid April. What puzzles me is the effect his sales have had on his remaining holding and why he is apparently happy to let it continue. When he first started selling around 6 months back the share price was 3.75p - 4p. It is now 1.6p - 1.62p. In effect TB has reduced the value of his remaining 30.9 million shares by 2.15p a share thus lowering the value of the remaining shares by almost £665k. Why he persists in this self destructive behaviour one can only surmise for he could have arranged an orderly market disposal had he wished but he chose not to do so. I can only conclude his actions are a symbol of his petulance at the current board of directors for some perceived slight.
11/12/2017
16:45
ydderf: Bear Case: The problem here is that there is unlikely to be any news of revenue over the next few months (unless you include research sales), and even if there are more CE applications approved that doesn't equate to revenue. Fact is the technology has been around for nearly three years in an AIM vehicle, the market cap of which has frequently been below £2m, and so by implication any potential acquirer has had lots of time to run the slide rule over it and consider an offer........Meanwhile the cash figures we have relate to 31st May. Undoubtedly they are lower now and revenue does not match expenses. As the months pass the probability of a further fund raise and dilution will come into focus. As far as I can see there are no constraints on the Board to issue more paper, they have hardly any skin in the game. Bull Case: The good news is that the success of this as an investment is not dependent on the 'caretaker' Board. A sales volcano may erupt beneath their feet but if so it will not have been of their doing. In addition to the in-house CE marked projects with e.g. Alliance, many research versions are now being used throughout the world to trial specific applications any one of which could result in a major diagnostic and commercial breakthrough. A typical project runs for two years plus, so any one of the research versions sold over two years ago could produce a result which nobody is anticipating. There is now a pipeline of such projects underway One modest commercial contract won would be a Richter event in relation to the puny market cap. As such, the share-price at this level is just option money
08/12/2017
13:16
curlly: good to see the share price going up.
22/11/2017
14:20
mikealig: A lot of shares but only worth around £750K at the current share price. As I mentioned before, the real key is whether the company is able to seriously monetise their technology. If they can, then this overhang could disappear in a flash. I'm not well enough informed to know what the potential clients would pay to license this technology. It sounds great but could anyone here put a figure on it?
20/7/2017
14:29
lr2: You will likely get the same, standard response that everyone else got. "The company has received several communications recently from shareholders expressing frustration at the drop in share price linked to ex-director’s dealing and to the lack of news flow on the CE mark. We cannot comment on the actions of ex directors or individual shareholders beyond what has already been announced. On progress with the CE mark, the team at Cambridge Computed Imaging responsible for completing this task have found the final stages to be slower than anticipated. There are, however, no major impediments foreseen that will prevent its completion, it is just taking a little longer. We are very confident that we will be in a position to obtain the the CE mark soon." Kind regards, Dr. Alastair J Riddell Chairman Feedback plc
07/10/2015
20:56
lr2: Feedback PLC, Don’t You Hate the Small Profit-Takers? Http://www.branduk.net/malcolm-stacey-of-shareprophets-feedback-plc-dont-you-hate-the-small-profit-takers/ Hello Share Bunnies. There was some interesting share movements after all the good news came out for Feedback (FDBK), the minnow capitalised at a mere £5 million. This firm which makes software to help in assessing cancers and other serious illnesses has been recording some big progress. The latest news to come in was that the National Health Service’s research arm has produced ‘an alert’ to the affect that this company is worth looking at. The share price put on 15%. It kept that level for most of the morning. Then the price began stepping up. There were small twitches until the golden share reached nearly a 50% rise on the day. This put Feedback at the top of the overall winners board. But not for long. The zenith proved to be a spike and the share inched down again to end the day at just 15% up. I checked the number of buys and sells throughout the day, and at no point did purchases exceed the sales. This rise and fall pattern is so common for penny shares these days. And I think we all know what’s going on.There is a large army out there who will take a profit, no matter what the great future might lie in store for the company. Feedback may not yet have recorded a recent profit, but it already nets £300,000 every 6 months by way of royalties and as their software is so desirable to find and treat serious cancers, I cannot see it failing to be a tasty go-er in the near future. Yet, so many holding the share are willing to take a short term profit. And they do that even though the spread is, as I look now, 20%. I think such short-term strategies are a mistake. They won’t realise much cash, because I notice the parcels of shares sold were largely tiny, many under £300. This could be a multi-bagger. I’m not daft enough to say that’s certain, or even probable, but I’m buying the shares and staying in for a few months at least. But what the heck? They say it’s never wrong to take a profit, and that does take a bit of arguing against. But personally I prefer a big profit to a small one. Time now for sampling duty – at the Punter’s Return.
06/10/2015
09:16
lr2: Thanks Blueball. I posted the NHS alert on here last Friday night (post #865) and nobody seemed to register the importance of it other than Britstox. Just as well Feedback got around to announcing the news today as my post had no effect on the share price. :)
15/5/2015
12:33
norbert colon: Stig/21. The good thing about these BBs is the fact that they are an open forum for investors, traders and in fact anyone to comment on a particular share / company and generally it's great to get the mixed views of all involved. All I would add re: some of the comments in this board from yourselves is that: 1) the RNS re: share price movement has to be read in the context that any RNS that does not specify contract values and relate them to forecasts for the business are just business as usual. All the recent announcement are business as usual in some respect as they are a function of the company trading and undertaking business; they are not YET material with respect to orders etc and hence I understand why they released that statement although I agree that given their very small mcap and early start-up stature, the flurry of positive news does seem ironic / coincidental. 2) Let's not call others on this board liars or delve to similar levels. Go short if you think FDBK is all hot air. Anyway, enjoy the weekend all and let's all hope for further news. Nobby
19/4/2015
19:10
alicia1983: Before the kidney stone trial announcement, the share price was 1-1-5p. Since the collaboration with the Oxford Stone Group RNS was released, the share price has moved to 1.5-1.8. From the RNS: "In the UK, an estimated 85,000 patients attend hospital with kidney stones each year..........which patients will benefit from lithotripsy would help to streamline treatment pathways and better allow clinicians to advise patients in choosing the right option for them. Similarly, using a non-invasive tool to better evaluate the composition of the stone facilitates personalised advice". But according to this: hxxp://parathyroid.com/kidney-stones.htm kidney stones are common throughout the world (between 3% and 5% of the population) so the numbers of potential beneficiaries (if it works) is quite appreciable. There is no guidance from the Company about what all this might mean, if anything, for potential revenues so shareholders have to form their own views - does anyone have any ideas?
Feedback share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:33 V: D:20180218 20:25:09